Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.53 |
| ▸ | GNPAT | O15228 | 1/20 | 0.43 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.42 |
| ▸ | NMT1 | P30419 | 5/20 | 0.42 |
| ▸ | NMT2 | O60551 | 4/20 | 0.42 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.40 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31480035 | 0.98 | FOLH1 (0.50) | FOLH1GNPATGLO1PTGS1GSTK1 | |
| SCHEMBL30099709 | 0.97 | FOLH1 (0.56) | FOLH1GNPATGLO1PTGS1GSTK1 | |
| SCHEMBL30099585 | 0.96 | FOLH1 (0.53) | FOLH1GNPATGLO1PTGS1GSTK1 | |
| SCHEMBL30099523 | 0.96 | FOLH1 (0.50) | FOLH1GNPATGLO1PTGS1GSTK1 | |
| SCHEMBL29655322 | 0.93 | FOLH1 (0.52) | FOLH1GNPATGLO1PTGS1GSTK1 | |
| SCHEMBL1370320 | 0.93 | FOLH1 (0.58) | FOLH1GNPATGLO1PTGS1GSTK1 | |
| SCHEMBL1370325 | 0.93 | FOLH1 (0.58) | FOLH1GNPATGLO1PTGS1GSTK1 | |
| SCHEMBL30099692 | 0.92 | FOLH1 (0.56) | FOLH1GNPATGLO1PTGS1GSTK1 | |
| SCHEMBL31676592 | 0.91 | NMT2 (0.43) | FOLH1GNPATGLO1NMT1NMT2 | |
| SCHEMBL31676589 | 0.91 | FOLH1 (0.50) | FOLH1GLO1PTGS1GSTK1NMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2024-04-04 | — | — | US | disclosed |
| US-11758933-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2023-09-19 | — | — | US | disclosed |
| EP-3368542-B1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11357246-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | FOLH1 1289/4885GNPAT 745/4885GLO1 3090/4885 |
| US-11357246-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | FOLH1 1289/4885GNPAT 745/4885GLO1 3090/4885 |
| US-11758933-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | FOLH1 1289/4885GNPAT 745/4885GLO1 3090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.